Triplet platinum-based combination sequential chemotherapy improves survival outcome and quality of life of advanced non-small cell lung cancer patients

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 5, 2012, Pages 1863-1867

  Chen, Li Kun ^a   Liang, Ying ^a   Yang, Qun Ying ^a   Xu, Fei ^a   Zhou, Ning Ning ^a   Xu, Guang Chuan ^a   Liu, Guo Zhen ^a   Wei, Wei Dong ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Maintenance therapy; NSCLC; Platinum based combinations; Sequential chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DEOXYCYTIDINE; DRUG DERIVATIVE; GEMCITABINE; NAVELBINE; PACLITAXEL; VINBLASTINE;

ADENOCARCINOMA; ADOLESCENT; ADRENAL TUMOR; ADULT; AGED; ARTICLE; BONE TUMOR; BRAIN TUMOR; CANCER STAGING; FEMALE; HUMAN; LIVER TUMOR; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; QUALITY OF LIFE; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE;

ADENOCARCINOMA; ADOLESCENT; ADRENAL GLAND NEOPLASMS; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DEOXYCYTIDINE; FEMALE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PROGNOSIS; PROSPECTIVE STUDIES; QUALITY OF LIFE; SURVIVAL RATE; VINBLASTINE; YOUNG ADULT;

EID: 84872681473     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.5.1863     Document Type: Article

References (19)

1. Belani CP, Barstis J, Perry MC, et al (2003). Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol, 21, 2933-9.
2. Belani CP, Pereira JR, von Pawel J, et al (2006). Effect of chemotherapy for advanced non-small cell lung cancer onpatients' quality of life. A randomized controlled trial. Lung Cancer, 53, 231-9.
3. Brodowicz T, Krzakowski M, Zwitter M, et al (2006). Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial. Lung Cancer, 52, 55-63.
4. Cappuzzo F, Ciuleanu L, Stelmakh S, et al (2010). Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol, 11, 521-9.
5. Cella DF, Tulsky DS, Gray G, et al (1993). The functional assessment of cancer therapy scale. Development and validation of the general measure. J Clin Oncol, 11, 570-9.
6. Chiappori A, Simon G, Williams C, et al (2005). Phase II study of first-line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung cancer. Oncology, 68, 382-90.
7. Ciuleanu T, Brodowicz T, Zielinski C, et al (2007). Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet, 374, 1432-40.
8. Edelman MJ, Clark JI, Chansky K, et al (2004). Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): Carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel. Clin Cancer Res, 10, 5022-6.
9. Fidias PM, Dakhil SR, Lyss AP, et al (2009). Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol, 27, 591-8.
10. Fisher MD, D'Orazio A (2000). Phase II and III trials: comparison of four chemotherapy regimens in advanced non small-cell lung cancer (ECOG 1594). Clin Lung Cancer, 2, 21-2.
11. Grossi F, Aita M, Follador A, et al (2007). Sequential, alternating, and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature. Oncologist, 12, 451-64.
12. Grossi F, Belvedere O, Fasola G, et al (2004). Sequential chemotherapy with paclitaxel plus cisplatin, followed by vinorelbine, followed by gemcitabine in advanced on-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 001). Lung Cancer, 46, 99-106.
13. Hosoe S, Komuta K, Shibata K, et al (2003). Gemcitabine and vinorelbine followed by docetaxel in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial of nonplatinum sequential triplet combination chemotherapy (JMTO LC00-02). Br J Cancer, 88, 342-7.
14. Non-small Cell Lung Cancer Collaborative Group (1995). Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ, 311, 899-90.
15. Pallis A, Agelidou A, Papakotoulas P, et al (2006). A multicenter phase II study of sequential vinorelbine and cisplatin followed by docetaxel and gemcitabine in patients with advanced non-small cell lung cancer. Lung Cancer, 52, 165-71.
16. Schiller JH, Harrington D, Belani CP, et al (2002). Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med, 346, 92-8.
17. Smith IE, O'Brien ME, Talbot DC, et al (2001). Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol, 19, 1336-43.
18. Socinski MA, Schell MJ, Peterman A, et al (2002). Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol, 20, 1335-43.
19. Westeel V, Quoix E, Moro-Sibilot D, et al (2005). Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer. J Natl Cancer Inst, 97, 499-506.